The future of pharmacotherapy for schizophrenia.

The future of pharmacotherapy for schizophrenia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The future of pharmacotherapy for schizophrenia. Abstract Text:

John M Kane,Anil Malhotra,

Although enormous progress has been made in the treatment of schizophrenia, and the use of existing pharmacologic agents can have a dramatic effect on the short- and long-term management of the disorder, enormous challenges and unmet needs continue to exist. Despite the introduction of a second generation of antipsychotic medications, many patients continue to derive inadequate benefits from available agents. Negative symptoms and cognitive dysfunction, and decrements in psychosocial and vocational functioning, often continue to persist despite our best available treatments. Medication adherence remains a constant challenge and has not been dramatically improved by the new-generation antipsychotic drugs. Since all currently marketed antipsychotic agents possess some degree of dopamine antagonist effects, the role of other neurotransmitters in the primary antipsychotic activity remains largely unclear. It is possible that different domains of disease effects might benefit from different specific classes of medications, yet research in this area is not highly developed. The promise of further discoveries in genetics leading to new treatment targets and better predictors of treatment response (both therapeutic and adverse) is enormously exciting, but these developments will require years of additional research. The field must balance the need to make the most informed and thorough use of available agents with a sense of both excitement and patience as we work toward other approaches.

The future of pharmacotherapy for schizophrenia. Publishing Authors By Initials

JM Kane,A Malhotra,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

The future of pharmacotherapy for schizophrenia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: World psychiatry : official journal of the World P

VOLUME: 2

Page Numbers: 81-6

Journal Abbreviation:

ISSN: 1723-8617

DAY: 1

MONTH: Jun

YEAR: 2003

The future of pharmacotherapy for schizophrenia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101189643

The future of pharmacotherapy for schizophrenia. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: The future of pharmacotherapy for schizophrenia. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for The future of pharmacotherapy for schizophrenia.

AFFILIATION: North Shore, Long Island Jewish Health System, The Zucker Hillside Hospital, 75-59 263 Street, Glen Oaks, NY 11004, USA.

Country: Italy

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: World Psychiatry

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The future of pharmacotherapy for schizophrenia Related Publications

• A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
• Anaesthetic considerations in a patient with wolff-Parkinson-white syndrome.
• Biosensor for total cholesterol estimation using N-(2-aminoethyl)-3-aminopropyltrimethoxysilane self-assembled monolayer.
• COMT genotype and manic symptoms in schizophrenia.
• COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance.
• Central sleep apnea: Pathophysiology and treatment.
• Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia.
• Corneal astigmatism with upper eyelid gold weight implantation using the combined high pretarsal and levator fixation technique.
• Cytokine release following recruitment maneuvers.
• DTNBP1 genotype influences cognitive decline in schizophrenia.
• Deep orbital sub-q restylane (nonanimal stabilized hyaluronic Acid) for orbital volume enhancement in sighted and anophthalmic orbits.
• Disrupted in schizophrenia 1 genotype and positive symptoms in schizophrenia.
• Emotion-based decision-making in healthy subjects: short-term effects of reducing dopamine levels.
• Food vacuole targeting and trafficking of falcipain-2, an important cysteine protease of human malaria parasite Plasmodium falciparum.
• Genioglossus premotoneurons and the negative pressure reflex in rats.
• Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics.
• Intense F-18 FDG uptake noted in a benign bone cyst.
• Loop around ear - a simple method for maintaining central venous line with ordinary venous cannula.
• Native manual tonsillectomy: A dangerous practice in Asir.
• Overexpression and purification of human calcitonin gene-related peptide-receptor component protein in Escherichia coli.
• Presumed fresh mutation hemophilia A presenting with subarachnoid hemorrhage in a newborn.
• Renal vein thrombosis: a case report.
• RluD, a highly conserved pseudouridine synthase, modifies 50S subunits more specifically and efficiently than free 23S rRNA.
• Scleral infiltration in orbitotemporal plexiform neurofibromatosis.
• The FEZ1 gene shows no association to schizophrenia in Caucasian or African American populations.
• The Golgi-associated protein GRASP is required for unconventional protein secretion during development.
• The future of pharmacotherapy for schizophrenia.
• The influence of aging on pharyngeal collapsibility during sleep.
• Upper airway myopathy is not important in the pathophysiology of obstructive sleep apnea.
• Use of computational modeling to predict responses to upper airway surgery in obstructive sleep apnea.